

()

:

(Coronary Heart Disease) : _____
ECG CHD CHD

(Tehran Lipid & Glucose Study)
ECG . Rose CHD

(OGGT)
: _____ CHD
% / / / ECG CHD
) / ECG CHD %
IHD .(/ p
% / CHD .(p< / p< / p)
(BMI) (p= / % / /)
: _____ CHD LDL/HDL CHD
CHD

/ / : / / : / / :

CHD
/
(CHD)
CHD

:

CHD

Rose

%

CHD

TLGS

CHD

ECG

PC-ECG

HDL

ECG

CHD

ECG

Rose

CHD

ECG

CHD

(IHD)

CHD

CHD

/

CHD

/

/

CHD

/

/

/

/

/

CHD

CHD

)

CHD

(ECG

CHD

IHD

Rose

(DBP)

(SBP)

(DBP)

(SBP)

)

/ (OGTT)

(2hPG)

(FBS)

ECG

(TG)

(TC)

Rose

TC

TG

IHD) CHD
 (ECG Rose Apo B (HDL-C) HDL
 non-HDL TG TC HDL-C LDL-C
 LDL/HDL HDL-C TG TC (LDL-C) LDL
 DBP SBP (WHR) BMI (C.f.a.s., Boehringer
 (Mannheim, Germany; cat. no. 759350

P CHD (CV)
 / / , TG /
 SPSS
 /
 DBP SBP
 TC TG LDL/HDL WHR BMI CHD
 WHO
 / P
 t

:


IHD		IHD		IHD		IHD	
(%)	(%)	(%)	(%)	(%)	(%)	*(%)	(%)
/	/	/	/	/	/	/	/
-	/	-	/	-	/	-	/
-	/	-	/	-	/	-	/
/	/	/	/	/	/	/	/
/	/	/	/	/	/	/	/

WHO

:IHD

CHD) ECG CHD
 (% / /) ()
 CHD
 (p= / / /)
 CHD
 ECG IHD
 (% /) IHD (% /)
 (% /) ECG
 (p= / % / /)
 ECG CHD
 (p< / % / /)
) CHD
 (ECG IHD
 CHD
 DBP SBP BMI
 non-HDL-C LDL-C TG TC
 (/ p)
 (p< /)

ECG TLGS
 IHD Rose
 (% /) IHD (% /)
 (% /) ECG
 Rose
 () % / / ECG IHD



HDL-C (p< /) CHD
 CHD
 CHD
)
 ()
 (p< / OR= /) (p= / OR= /)
 / OR= /) BMI (p= / OR= /)
 /) LDL/HDL (p= / OR= /) WHR (p= /)
 CHD (p= / OR= /) IHD (p< / % /)
 (p< / % /)
 ()

(≤)
 (% / /) %
 (% / % /) IHD
 (% / /) ECG
 IHD
 (p< / % /)
 (p< / % /)
 ()

(=)	(=)	
± *	±	()
†	/	(%)
/ †	/	(%)
/ ± / *	/ ± /	(kg/m ²)
± *	±	(cm)
± *	±	(cm)
/ ± / *	/ ± /	
/ ± / *	/ ± /	
/ ± / *	/ ± /	(mm/Hg)
/ ± / *	/ ± /	(mm/Hg)
/ *	/	(/ ≤)
/ ± / *	/ ± /	(mg/dL)
/ ± / *	/ ± /	(mg/dL)
/ ± / *	/ ± /	(mg/dL)
/ ± / *	/ ± /	(mg/dL)
/ ± / *	/ ± /	(mg/dL) LDL
/ ± /	/ ± /	(mg/dL) HDL
/ ± / *	/ ± /	(mg/dL) HDL
/ ± / *	/ ± /	LDL/HLD

.p< / † p< / * .

	(SE)	β	
/ (/ /) *	/	/	
/ (/ /) *	/	/	
/ (/ /) *	/	/	(mm/Hg)
/ (/ /) †	/	/	(kg/m ²)
/ (/ /) †	/	/	
/ (/ /) †	/	/	(mg/dL)
/ (/ /) *	/	/	LDL/HLD

LDL/HLD

.p< / † p< / *

ECG

CAD

CAD

CHD

IHD

% /

CAD /

ECG

Rose

CAD

ECG

MI

CAD

% /

% /) .

(p< /

%

% /)

CAD

(p< /

%

(% /)

% /)

ECG

(% /)

(%)

(p< /

% /

CAD

CAD

NHANES

(p< /

%

%)

% /

IHD

% ECG

(% /)

% /

≤

% /

CAD

CAD

CAD

FORD

ECG

(MI)

≥

HDL

LDL

TC/HDL

LDL/HDL

CAD

CAD

CAD

HDL

(CHD)

CAD

CAD HDL
 LDL
 HDL CAD
 LDL
 CAD LDL/HDL
 CHD CAD CAD WHR BMI
 WHR BMI
 CAD CAD
 CAD
 MI WHR BMI
 % /
 ECG IHD WHR
 CAD IHD BMI
 BMI WHR
 CHD
 LDL/HDL
 CAD
 HDL
 HDL

References

1. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. *Am J Med.* 1984; 76: 4-12.
2. Keil U. The Worldwide WHO MONICA Project: results and perspectives. *Gesundheitswesen* 2005; 67: Suppl 1: S38-45.
3. Thom TJ, Kannel WB, Silbershatz HD, Agostino RB. Incidence, prevalence and mortality of cardiovascular disease in the United States. In: Lutz JF, Hurst JW, Editors. *Hurst the Heart*. 9th ed. New York: McGraw Hill, 1998: 3.
4. Sytkowski PA, Agostino RB, Belanger A, Kannel WB. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham heart study. *Am J Epidemiol* 1996; 143:338-50.
5. World health organization, Eastern Mediterranean Regional office. *Prevention and control of cardiovascular disease*. Alexandria, WHO-EMRO 1995: 24.
6. Zali M, Kazem M, Masjedi MR. Health and disease in Iran. Deputy of research, Ministry of health 1993. Bulletin No.10.
7. Popkin BM, Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. *Int J Obes Relat Metab Disord* 2004; 28: Suppl 3: S2-9.
8. Prentice AM. The emerging epidemic of obesity in developing countries. *Int J Epidemiol* 2006; 35: 93-9.
9. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. *Diabetes Res Clin Pract* 2003; 61: 29-37.
10. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). *Soz Praventivmed.* 2002; 47: 408-26.
11. Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid

-
- and Glucose Study (TLGS), 1999-2000. *J Hum Hypertens* 2002; 16: 305-12.
12. Azizi F, Rahmani M, Emami H, Madjid M. Tehran Lipid and Glucose Study: Rationale and Design. *CVD Prevention* 2000; 3: 242-7.
 13. Christiansen DH, Hosking JD, Dannenberg AL, Williams OD. Computer-assisted data collection in multicenter epidemiologic research. The Atherosclerosis Risk in Communities Study. *Control Clin Trials* 1990; 11:101-15
 14. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. *Br J Prev Soc Med* 1977; 31: 42-8.
 15. Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurements and classification. Boston, MA: John Wright PCG Inc: 1982.
 16. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. *Am Heart J* 2000; 139: 371-7.
 17. Friedwald WT, Levy RI, Fredridson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
 18. Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. *Acta Cardiol* 1999 ; 54: 257-63.
 19. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. *Am Heart J* 2000; 139: 371-7.
 20. Mohan V, Deepa R, Rani SS, Premalatha G. Chennai Urban Population Study. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai Urban Population Study (CUPS No. 5). *J Am Coll Cardiol* 2001; 38: 682-7.
 21. Al-Nozha MM, Arafah MR, Al-Mazrou YY, Al-Maatouq MA, Khan NB, Khalil MZ, et al. Coronary artery disease in Saudi Arabia. *Saudi Med J* 2004; 25: 1165-71.
 22. Chen CH, Chuang JH, Kuo HS, Chang MS, Wang SP, Chou P. Prevalence of coronary heart disease in Kin-Chen, Kinmen. *Int J Cardiol* 1996; 55 :87-95.
 23. Wilcosky T, Harris R, Weissfeld L. The prevalence and correlates of Rose Questionnaire angina among women and men in the Lipid Research Clinics Program Prevalence Study population. *Am J Epidemiol*. 1987; 125: 400-9.
 24. Owen-Smith V, Hannaford PC, Elliott AM. Increased mortality among women with Rose angina who have not presented with ischaemic heart disease. *Br J Gen Pract*. 2003; 53: 784-9.
 25. Mirmiran P, Mohammadi F, Allahverdian S, Azizi F. Measurement of total energy requirement in adults: prospective Tehran Lipid and Glucose Study. *Pajouhandeh, J Shaheed Beheshti Univ Med Sci* 2001; 6 :157-66 (in Farsi).
 26. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med*. 2001; 161: 397-405.
 27. Yusef s, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. *Lancet* 2005; 366: 1640-9.
 28. Azizi F, Raiszadeh F, Salehi P, Rahmani M, Emami H, Ghanbarian A, et al. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study. *Nutr Metab Cardiovasc Dis* 2002; 12: 80-9.
 29. Simpson RJ Jr, White A. Getting a handle on the prevalence of coronary heart disease. *Br Heart J* 1990; 64: 291-2.